Month: January 2016

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

Posted on

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The report provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The Report gives insights on 30+ products with 15+ different technologies. It also includes around 20+ companies which are active in this field. DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 3,750 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

Phone: +91-11-45689769, +91 9650213330

Website: http://delveinsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

“Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” – A DelveInsight Report

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio.

Reports Highlights:

·      CAR-T cell Therapy Pipeline scenario
·      Collaborations & partnering deals
·      Current Prominent Research Areas and Key Players
·      Pipeline product profiles CAR-T Technologies and Targeted Antigens
·      Licensing opportunities
·      Market Drivers and Barriers

Report Coverage:

40+ companies,100+ products and 24 different technologies

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” emphasizes on the currently active CAR-T cell products in research and development. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens.

The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2,450 as a single user license, USD 4,900 as a site license and USD 7,350 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

Phone: +91-11-45689769, +91 9650213330

Website: http://delveinsight.com

 About Us

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Zemplar -Drug Insights, 2016 – A DelveInsight Report

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report Zemplar -Drug Insights, 2016 to its portfolio. With this launch DelveInsight now has 400+ Reports on Drug Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The Drug Insight Reports provides client with details on global Zemplar -Drug Insights, 2016. It comprehensively includes:

  • Marketed details and the Global API Manufacturers details across the globe along with the location
  • Total sales estimation along with sales forecast till 2018
  • Detailed clinical assessment, patent information
  • SWOT analysis

The report on Zemplar -Drug Insights, 2016 will help in evaluating market scenario and harness opportunities for development by identifying the key patent expiry details and exclusivity with respect to Zemplar. In addition to this the detail sales forecast and SWOT analysis will help companies in finding collaborations and licensing partners.

DelveInsight is offering the Report at a price of USD 1000 as a single user license, USD 2000 as a site license and USD 3000 as a Global/Enterprise License.

For more information on API insight Reports, email at info@delveInsight.com

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

+91-11-45689769, +91-9650213330

 About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

 

Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.
The Indication pipeline Insight Reports provides client with Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 products across the globe. It comprehensively includes:
  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 10 are in phase III, 25 in phase II, 49 in phase I, 2 in phase 0 13 in pre – clinical and 30 inactive and 6 are discontinued.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Head and Neck Squamous Cell Carcinoma helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

 

DelveInsight is offering the Report at a price of US 2,250 as a single user license, USD 4,500 as a site license and USD 6,750 as a Global/Enterprise License.
For more information on Pipeline Insight Reports, email at info@delveInsight.com
About Us:
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

  Pancreatic Cancer-Pipeline Insights, 2016

Posted on

DelveInsight, the leading market research and consulting company has added new report   Pancreatic Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.
The Indication pipeline Insight Reports provides client with details Pancreatic Cancer Pipeline products across the globe. It comprehensively includes:
  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 12 are in phase III, 39 in phase II, 39 in phase I, 13 in pre – clinical and 41 in dormant phase.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
Pancreatic Cancer -Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Pancreatic Cancer helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.
DelveInsight is offering the Report at a price of USD 2,250 as a single user license, USD 4,500 as a site license and USD 6,700 as a Global/Enterprise License.
For more information on Pipeline Insight Reports, email at info@delveInsight.com

 

Contact Us:
DelveInsight Business Research
New Delhi-110075, India
Phone: +91-11-45689769, +91 9650213330
Website: http://delveinsight.com
About Us
DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

 

 

Peripheral Lung Cancer-Pipeline Insights, 2016

Posted on Updated on

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The Indication pipeline Insight Reports provides client with details on Peripheral Lung Cancer Pipeline products across the globe. It comprehensively includes:

  • Comparative study of drugs under development.
  • Information on several other drugs as well among which 1 are in phase III, 5 in phase II, 3 in phase I, 3 in pre – clinical and 6 in dormant phase.
  • R&D activities and technologies used along with the pipeline molecules in development.
  • Information related to collaborations, in-licensing and out-licensing deals.
  • Stages of development of pipeline molecules.
  • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

Peripheral Lung Cancer-Pipeline Insights, 2016 Report envisages Pipeline Intelligence by identifying the key players along with their potential pipeline molecule. Therefore DelveInsight’s report on Peripheral Lung Cancer helps to optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market. In addition, it assesses the major market drivers and barriers in development of Pipeline molecules which helps to understand market for collaborations and licensing deals.

DelveInsight is offering the Report at a price of US 1,450 as a single user license, USD 2,900 as a site license and USD 4,500 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight’s Market Research Reports, 2016

Posted on Updated on

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates.

After tremendous success last year, Delve Insight – Business Consulting & Market Research Company is back again with 2016 updated edition of reports.

Moving forward, this year DelveInsight has broached into new report verticals –Epidemiology and Market Insights in its portfolio.

In addition to that we have also entered into consulting services/custom projects as per interest area of the clients.

DelveInsight’s consulting services includes Market Assessment (Market Size, Market Forecasting and Epidemiology for Indications) & Development Strategies, Competitive Intelligence & Landscaping and Licensing Opportunities.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.